StaniPharm Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 7
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 4

StaniPharm General Information


Developer of drug substances and differentiated drug products designed to offer improved clinical performances over existing formulation. The company's products use Supercritical Fluid (SCF) technology and formulation techniques, nabling life science industry to efficiently move their product along the development path and get high-quality results using cost-effective supercritical fluid technologies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 5 rue Jacques Monod
  • BP 10
  • 54250 Champigneulles
  • France
+33 03 00 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

StaniPharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 00000 Completed Profitable
1. Early Stage VC 15-Jun-2010 00000 00000 Completed Profitable

StaniPharm Executive Team (3)

Name Title Board Seat Contact Info
Frantz Deschamps Co-Founder, Chief Executive Officer & President
Fabrice Leboeuf Chef de projet chez & Co-Founder
Jennifer Jung Co-Founder

StaniPharm Investors (4)

To view StaniPharm‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ADER Investissements Venture Capital Minority 000 0000 000000 0
Aqua Asset Management Asset Manager Minority 000 0000 000000 0
ILP Sadepar Gestion PE/Buyout Minority 000 0000 000000 0
Incubateur Lorrain Accelerator/Incubator Minority 000 0000 000000 0

Ready to get started?

Request a free trial